Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy, such as Gliadel wafer and O6-benzylguanine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving Gliadel wafer together with O6-benzylguanine works in treating patients with recurrent glioblastoma multiforme.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Collaborator: National Cancer Institute (NCI)
• Treatments: Carmustine; O(6)-benzylguanine

Criteria

INCLUSION CRITERIA:

DISEASE CHARACTERISTICS-

• Histologically confirmed recurrent glioblastoma multiforme (including gliosarcoma) which can be confirmed, if not earlier, by intraoperative pathological diagnosis on frozen section

• Evidence of a unilateral, single focus of measurable Central Nervous System (CNS) neoplasm on contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) scan that is supratentorial and measures ≥ 1.0 cm in diameter

PATIENT CHARACTERISTICS-

• Greater than or equal to 18 years old

• Life expectancy of greater than 12 weeks

• Karnofsky performance status greater than or equal to 60%

• Absolute neutrophil count ≥ 1,000/millimeters (mm)³

• Platelet count ≥ 100,000/mm³

• Total Serum Bilirubin < 2 times upper limit of normal (ULN)

• Serum glutamic oxaloacetic transaminase (SGOT) < 3 times ULN

• Blood urea nitrogen (BUN) < 1.5 times ULN

• Creatinine < 1.5 times ULN

• Negative pregnancy test

• Recovered from any effects of major surgery

• Patients or legal guardian must give written, informed consent.

PRIOR CONCURRENT THERAPY-

• At least 2 weeks since prior surgical resection (if conducted) and recovered, unless there is unequivocal evidence of tumor progression

• At least 4 weeks since prior radiotherapy or chemotherapy (6 weeks for nitrosoureas), unless there is unequivocal evidence of tumor progression.. However, patients treated with chemotherapeutic agents such as etoposide who would normally be retreated after shorter intervals (eg, 21 days on, 7 days off schedule) may be treated at the usual starting time even if less than 4 weeks from the last prior dose of chemotherapy.

EXCLUSION CRITERIA:

• Patients who have not recovered from surgery

• Patients who are not neurologically stable for 2 weeks prior to study entry

• Patients who are poor medical risks because of non-malignant systemic disease as well as those with acute infection treated with intravenous antibiotics

• Frequent vomiting or medical condition that could interfere with oral medication intake (e.g., partial bowel obstruction)

• Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention

• Known HIV positivity or AIDS-related illness

• Pregnant or nursing women

• Women of childbearing potential who are not using an effective method of contraception. Women of childbearing potential must have a negative serum pregnancy test 24 hours prior to administration of study drug and be practicing medically approved contraceptive precautions.

• Men who are not advised to use an effective method of contraception

• Patients taking immuno-suppressive agents other than prescribed corticosteroids

• Patients who have had prior treatment with Gliadel Wafers.